Therapeutic vaccines are provided to the body during treatment of specific diseases. This vaccine triggers and strengthens the immune response of the body to act against a disease. In 2011, the global therapeutic vaccines market was valued at $294 million. This vaccine has expanded the horizon of chronic disease treatment. However, there is a need to get a vaccine for specific disease to be approved by the FDA. Increasing cases of chronic diseases and need for effective treatment is acting as key driver for this market. Various pharmaceutical companies are working to develop novel vaccines for diseases such as lung cancer, breast cancer, Alzheimer, etc. However, these vaccine developments are in pipeline and yet to be commercialized.
Inefficient Research & development and reimbursement policies are primary factors restraining the market. Furthermore, as the market is in nascent stage, strict regulatory implications are also expected to deter growth. However, as the vaccine carries potential to treat many chronic diseases, these restraints would get weaker with time. This report delivers micro level analysis of the therapeutic vaccine market and its opportunities in various disease treatments.
Key market players profiled in this report include Affiris, Antigenics, Argos Therapeutics, Bavarian Nordic, Biovest International, Celldex Therapeutics, Cel-Sci, Celtic Pharma, Curevac And Cytos Biotechnology.
KEY MARKET SEGMENTS